Group 1 - The medical device sector increased by 0.19% on January 29, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] - Key stocks in the medical device sector showed varied performance, with Sanyou Medical rising by 5.12% to a closing price of 22.60 [1] Group 2 - Major stocks that declined included Daan Gene, which fell by 9.96% to a closing price of 6.87, and Cap Bio, down 9.88% to 7.94 [2] - The medical device sector experienced a net outflow of 376 million yuan from institutional investors, while retail investors saw a net inflow of 201 million yuan [2][3] - Notable net inflows from retail investors were observed in stocks like Lepu Medical, which had a net inflow of 42.29 million yuan [3]

证券日报网讯1月27日，欧普康视（300595）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总人数为63118户。 ...

证券日报网讯1月27日，欧普康视（300595）在互动平台回答投资者提问时表示，公司主营产品主要通 过专业视光渠道销售，公司一直通过眼视光专业学术会议和展会、技术培训等渠道推广，公司计划在这 些有效的渠道之外再重点拓展新媒体上的宣传推广。 ...

证券日报网讯1月23日，欧普康视（300595）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总人数为63118户。 ...

（编辑 丛可心） 证券日报网讯 1月23日，欧普康视在互动平台回答投资者提问时表示，长期以来，"欧普康视"这一名称 已伴随公司发展多年，不仅在行业内积累了深厚的品牌口碑与市场辨识度，也承载了广大投资者与消费 者的信任。综合考量品牌传承价值、现有商标体系稳定性、全产业链业务布局的适配性等多重因素，目 前公司暂无名称变更相关规划。 ...

证券日报网讯1月20日，欧普康视（300595）在互动平台回答投资者提问时表示，如有对外投资事项会 按照规则披露。 ...

Group 1 - The company OPPLE Vision (300595.SZ) is currently in the small batch supply phase for its product "Duozhi" and has not yet reached full-scale production [1] - The company's self-owned brand is in preparation, indicating future product launches [1] - Eye health products have been sold to Southeast Asia through cross-border e-commerce and are currently in the promotion stage [1] Group 2 - The audio glasses from the company's associate, Leo Huiding, have just been launched for sale [1] - The company will disclose any investment or acquisition matters according to regulations [1]

Policy Developments - The State Administration for Market Regulation has approved the national standard for "Classification and Determination of Traditional Chinese Medicine Constitution," which will be implemented from April 1. This standard categorizes nine basic types of TCM constitution and aims to enhance health literacy and optimize health service models [2]. Medical Device Approvals - Opcon Vision's application for the registration of "soft hydrophilic contact lenses" has been accepted by the National Medical Products Administration, currently in the acceptance phase [4]. - Livzon Pharmaceutical announced that its clinical trial application for injectable brexpiprazole microspheres for treating schizophrenia has been accepted by the National Medical Products Administration [5]. Capital Markets - AstraZeneca will acquire the remaining 50% equity of Westman Biotech's GPC3 armored CAR-T therapy in China, with a potential payment of up to $630 million, including upfront and milestone payments [7]. - Aote Biological's controlling shareholder has proposed a share buyback plan using funds from its IPO, with a total amount between RMB 100 million and RMB 200 million [8]. Industry Developments - Alibaba Health has launched its self-developed AI medical model "Hydrogen Ion," which is now in practical application, targeting clinical and research fields. This move complements Alibaba's existing health service strategies [10][11]. - Jiangzhong Pharmaceutical has changed its name to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will also change its stock abbreviation to "China Resources Jiangzhong," while keeping the stock code unchanged [12]. Shareholder Actions - Liaoning He Eye Hospital Group has received a notice from a major shareholder planning to reduce its stake by up to 3,106,074 shares, representing 1.97% of the total share capital, between February 7 and May 6, 2026 [14].

证券代码：300595 证券简称：欧普康视 公告编号：2026-003 1、受理号：CQZ2600102 2、产品名称：软性亲水接触镜 3、注册分类：境内Ⅲ类 欧普康视科技股份有限公司 关于申报医疗器械注册证获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局出具的《受理通知书》，公司申请医疗器械产品"软性亲水接触镜"注册 申请已获国家药品监督管理局受理。具体情况如下： 一、申请注册产品基本情况 4、临床用途：日戴，矫正屈光不正 5、申请人：欧普康视科技股份有限公司 6、结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、产品的审批流程 1、目前所处注册审批阶段：注册申请受理。 2、后续所需审批流程：技术审评。 三、同类医疗器械的市场状况 1、同类医疗器械在国内外的研究现状 软性亲水接触镜的临床研究在国外已有多年，此产品为含水量 60%的日抛透 明彩片，设计为多焦设计，配戴美观舒适，同时具有良好的视力矫正效果。 2、同类医疗器械在国内外的生产 ...

Shareholder Reductions - RS Technologies and Cangyuan Investment plan to reduce their holdings by no more than 3% in Youyan Silicon [1] - Yuexiu Capital intends to sell no more than 1% of the total share capital of CITIC Securities [1] - Multiple shareholders of Ruimaite plan to collectively reduce their holdings by no more than 4.98% [1] - The controlling shareholder of Brother Technology plans to reduce its holdings by no more than 2% [1] - Jinggangshan Chengxing intends to reduce its holdings in Guanggang Gas by no more than 0.9997% [1] - The controlling shareholder of Lianchuang Optoelectronics, Electronic Group, plans to reduce its holdings by no more than 2% [1] - Shenzhen Jun Tian, a shareholder of Chengdu Xian Dao, plans to reduce its holdings by no more than 2.51% [1] - Shareholder Fan Jun of Xidi Micro plans to reduce no more than 251,230 shares [1] - Shareholder Cheng Gao Century of Decai Co., Ltd. plans to reduce 4.1973 million shares [1] - Hangzhou Xintou and its concerted action party Hangzhou Haoyue have cumulatively reduced 1.29% of shares in Meinian Health [1] - Guotou Chuangye Fund has cumulatively reduced 1.06% of shares in Fuchuang Precision [1] - New Momentum Fund has cumulatively reduced 0.9926% of shares in Shannon Chip Creation [1] - Deputy General Manager Li Zuqing of Guangli Technology plans to reduce no more than 701,600 shares [1] Other Notable Events - Yuan Zhishuang of Dingxin Communications is under investigation by the Securities Regulatory Commission for suspected short-term trading of company shares [1] - Shimao Energy has terminated its plans for a change in control [1]